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Abstract
In evolution strategies aimed at isolating molecules with new functions, screening for the desired phenotype is generally
performed in vitro or in bacteria. When the final goal of the strategy is the modification of the human cell, the mutants
selected with these preliminary screenings may fail to confer the desired phenotype, due to the complex networks that
regulate gene expression in higher eukaryotes. We developed a system where, by mimicking successive infection cycles
with HIV-1 derived vectors containing the gene target of the evolution in their genome, libraries of gene mutants are
generated in the human cell, where they can be directly screened. As a proof of concept we created a library of mutants of
the human deoxycytidine kinase (dCK) gene, involved in the activation of nucleoside analogues used in cancer treatment,
with the aim of isolating a variant sensitizing cancer cells to the chemotherapy compound Gemcitabine, to be used in gene
therapy for anti-cancer approaches or as a poorly immunogenic negative selection marker for cell transplantation
approaches. We describe the isolation of a dCK mutant, G12, inducing a 300-fold sensitization to Gemcitabine in cells
originally resistant to the prodrug (Messa 10K), an effect 60 times stronger than the one induced by the wt enzyme. The
phenotype is observed in different tumour cell lines irrespective of the insertion site of the transgene and is due to a change
in specificity of the mutated kinase in favour of the nucleoside analogue. The mutations characterizing G12 are distant from
the active site of the enzyme and are unpredictable on a rational basis, fully validating the pragmatic approach followed.
Besides the potential interest of the G12 dCK variant for therapeutic purposes, the methodology developed is of interest for
a large panel of applications in biotechnology and basic research.
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Introduction
Broadening the repertoire of natural molecules and generating
variants that confer new phenotypes to human cells are appealing
perspectives for the development of biomedical applications, and
for understanding fundamental cellular processes. To this end, in
classical procedures, libraries of mutants are generated in vitro by
degenerated PCR or DNA shuffling, and then screened on
biochemical bases or with genetic tests in bacteria [1]. However,
when the modification of human cells is sought, the mutants
identified in these preliminary screenings often do not confer the
desired phenotype due to differences in protein folding, post-
translational modifications, and to the complex epistatic network
that regulates the expression of the phenotype in the cells of higher
eukaryotes. Alternatively, the library can be cloned in eukaryotic
expression vectors for the screening step, albeit with the drawback
of a considerable loss of complexity. The generation and screening
of libraries of mutants directly in human cells would constitute an
ideal solution to circumvent these problems. Nature provides
organisms that are perfectly exploitable for this purpose: retrovi-
ruses. Indeed, after entry into the target cell, the viral polymerase
(reverse transcriptase, RT) converts the viral genomic RNA,
through an error-prone process that generates genetic diversity,
into double-stranded DNA, which is then permanently integrated
in the genome of the cell.
The human immunodeficiency virus (HIV-1) is the retrovirus
with the strongest mutation rate, and constitutes therefore the
ideal candidate for developing such approaches. During the
process of Reverse Transcription, point mutations are introduced
in the proviral DNA with a rate of 1–3.461025 nt/cycle [2–4] and
genetic diversity is further amplified by recombination [5,6]. We
report here the development of a new methodology (called
‘‘Retrovolution’’) aimed at generating and screening libraries of
cellular genes directly in human cells. In Retrovolution the error-
prone replication machinery of HIV-1 is diverted to drive the
evolution of cellular genes: by performing successive infection
cycles of cell cultures with HIV-1-derived viral vectors containing
the sequence target of the evolution inserted in their RNA,
libraries of gene mutants are generated in human cells, where they
can be directly screened for the desired phenotype. A system for
the evolution of non-viral sequences based on the use of
engineered HIV-1 had been previously developed for the
optimization of the Tetracycline-regulated expression system [7].
In that system, the isolation of an improved phenotype was strictly
linked to the efficiency of replication of the viral particle, whereas
in Retrovolution selection is not linked to viral replication and the
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use of replication-defective, non-cytopathic vectors allows the
isolation and expansion of cells with the desired phenotype, which
is not possible when replication-competent HIV particles are used.
While relatively simple proteins or sequences, as a modified tag
or reporter gene, have traditionally constituted the target for
setting up evolution procedures [8,9], to evaluate the power of the
Retrovolution system we aimed at generating and isolating
variants of a protein modifying a complex cellular phenotype,
which could have a potential therapeutic interest. Namely, we
wished to mutagenize the human deoxycytidine kinase (hdCK,
NM_000788.2 mRNA NCBI accession number) gene with the
goal of isolating an enzyme variant able to increase the sensitivity
of cells to a widely used category of anticancer compounds,
deoxycytidine (dC) analogues. The hdCK, physiologically involved
in the phosphorylation of deoxycytidine, deoxyadenosine and
deoxyguanosine in the salvage pathway for the deoxyribonucle-
otide biosynthesis, is a pivotal enzyme in the activation of
deoxycytidine analogues used in chemotherapy (AraC and
Gemcitabine, used in the treatment of leukemias and solid
tumours). These compounds, administered as nucleosides, must
be transformed by cellular enzymes in their triphosphate form to
become active and induce apoptosis in the cell by interfering with
DNA replication and repair [10]. The first phosphorylation step,
catalyzed by the human deoxycytidine kinase, determines the
overall efficiency of the process [11]. Accordingly, there is a direct
correlation between the level of dCK expression and the sensitivity
to deoxycytidine analogues in different types of tumor [12,13].
The appearance of resistance forms among tumor cells, often due
to a loss of dCK activity, and the toxicity of high concentrations of
nucleoside analogues for non-tumor cells, constitute the major
limits of the treatments with these compounds [14,15]. The
sensitization of cancer cells to low doses of drugs by insertion of a
gene coding for a drug-metabolizing enzyme constitutes an
appealing approach for gene therapy applications [16–18]. A
dCK variant that could preferentially phosphorylate nucleoside
analogues with respect to the natural substrate deoxycytidine, and
therefore induce cell suicide upon exposure to low concentrations
of prodrug, would constitute a good candidate for these ‘‘suicide
gene’’ therapies in cancer treatment, but also in transplantation
medicine. In this case, indeed, it would provide a human (and
therefore poorly immunogenic) gene to use as negative selection
marker to insert in transplanted cells to counteract their eventual
uncontrolled proliferation in vivo.
So far, attempts at constructing a dCK mutant with improved
ability in phosphorylating deoxycytidine analogues have been
based on the information obtained from the 3D structure of the
protein [19,20]; these dCK variants based on the rational design
displayed an overall increased catalytic activity, resulting in a
highly improved affinity for the natural substrate and a less
improved affinity for the prodrug, which is not predictive of the
induction of a sensitization phenotype in vivo. By evolving the dCK
gene with Retrovolution procedure we could directly screen for
dCK variants inducing cell death in presence of doses of the
deoxycytidine analogue Gemcitabine lower than the ones needed
to kill cells bearing a wt dCK, and this allowed us to isolate a
mutant consistently sensitizing cancer cells to the prodrug.
Results
The Retrovolution system
The Retrovolution system, outlined in Figure 1, is based on the
insertion of the gene target of the evolution process in the genomic
RNA (gRNA) of conditional replication-defective, HIV-1 derived
vectors pseudotyped with the Vesicular Stomatitis Virus envelope
(VSV-G) (Figure 1A). Repeated cycles of transduction of producer
cells with these vectors, as indicated in Figure 1B, mimic successive
infection cycles by HIV-1, during which mutations will be inserted
in the gRNA and re-shuffled by recombination [21,22], an event
favored when transductions are performed at a high Multiplicity
Of Infection (MOI). During the procedure, HIV-1 Reverse
Transcriptase will introduce mutations all along the viral gRNA
and, while those falling in functional regions of the vector will be
selected (positively or negatively), the others, including those falling
in the target gene, will accumulate in an unbiased fashion. This
process generates a library of mutants of the target gene directly
inserted into the vector tasked with delivering the transgene to the
human cell, and requires minimal intervention from the experi-
menter. During the evolution procedure, cells that did not receive
the viral vector and therefore do not contain an integrated proviral
DNA are removed by puromycin treatment (the puromycin
resistance gene being inserted as a selectable marker in the gRNA
of the vectors, see Figure 1A). As an alternative, GFP can be used
as a selectable marker instead of puroR and successfully transduced
cells can be sorted by FACS at every round: the use of GFP would
fasten the evolution procedure (a complete puromycin selection
takes three to four days), but would require a much more
important manual intervention. The average number of positions
that will be mutated in the target gene will depend on the number
of ‘‘infection cycles’’ performed, on the size of the target gene itself,
and on the mutation rate of the reverse transcription process, as
outlined in Figure 2A. Once reached the ideal complexity, the
library of mutants will be screened by transducing target cells (the
human cells to which the intended phenotype is to be conferred) at
a low MOI (%1) to minimize the possibility that one cell will
receive more than one vector, followed by clonal analysis
(Figure 1B). As the vectors are pseudotyped with the VSV
envelope, which can infect virtually any kind of mammalian cells,
the library can be screened in all human cell types.
Retrovolution generates genetic diversity
A library of dCK variants was generated by using the dCK
coding sequence (dCK-cs) as the target gene (Figure 1A) of the
Retrovolution procedure. By sequencing part of the library after 9
Author Summary
We exploited the error-prone replication machinery of HIV-
1 and its ability to stably introduce transgenes in human
cells to develop a novel system, Retrovolution, to generate
libraries of mutants of cellular genes. When libraries are
screened to isolate variants that modify the phenotype of
the human cell for biomedical applications or basic
research, false positives often arise from the classical
screening procedures performed in vitro or in bacteria.
Retrovolution allows an easy screening of the libraries
directly in the human cell, where they are generated. We
describe the creation and screening of a library of the hdCK
(a human kinase activating several anticancer compounds)
gene, to identify variants increasing the sensitivity of cancer
cells to treatment with low, poorly toxic doses of the
anticancer drug Gemcitabine. We isolated a dCK variant
inducing death in tumour cells at doses up to 300 times
lower than those required for killing non-engineered cells.
The mutant presents mutations unpredictable on structural
basis and revealed a change in enzymatic properties that
accounts for the observed cellular effect. Besides the
intrinsic interest of the mutant identified, these results fully
validate Retrovolution as a mutagenesis system with broad
applications in applied and basic research.
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cycles of transduction we could calculate an ongoing mutation rate
of 161024 nt/infectious cycle. Based on this, the library was
screened upon reaching generation 16, at which a complexity of 1.5
mutated positions per dCK-cs (783 bp) was expected (Figure 2A). A
further sequencing of a subset of the library at this generation
confirmed the presence of 1.4 mutated positions per dCK gene
(Table 1). In the dCK variants sequenced all kinds of mutations
were present with a bias towardG.A transitions (62.3%), consistent
with the mutational pattern of HIV-1 RT [23]. While the
sequencing of the dCK gene at different generations of the
Retrovolution system confirmed that mutations were inserted
randomly along the gene (Figure 2B), the sequencing of the viral
backbone of the corresponding clones revealed a consensus of 12
mutations in the U3 region of each vector (Figure 2C). These
consensus mutations appeared in the promoter region of HIV-1
LTR since the F8 generation and were fixed in the population ever
since. Moreover, their nature diverged from the typical HIV-1
mutation pattern since the percentage of G.A transitions was
consistently lower (33%). No mutations were instead found in the
other cis-acting regions essential for genome packaging, reverse
transcription, integration and nuclear export. Overall, this strongly
suggests that the viral sequences underwent selection for an
optimized transcription of the genomic RNA from the U3 promoter
in the specific context of the producer cells, while preserving the
functionality of the vector, and allowing the production of a library
of randomly mutated variants of the target gene.
Identification of mutants of the human dCK conferring
an increased sensitivity to Gemcitabine
To screen the library for the presence of dCK variants that
confer an increased sensitivity to low concentrations of the
Figure 1. The Retrovolution system. Panel A. General structure of genomic RNAs for Retrovolution (top) and specific structure of the genomic
RNA used in this study (bottom). Expression of the ‘‘target gene’’ is driven by an eukaryotic promoter (inducible or not, in this case the constitutive
promoter of the human elongation factor 1-alpha, EF1-alpha); a selectable marker (here, the puromycin-resistance gene) is transcribed from a second,
independent promoter (in this case the human phosphoglycerate kinase gene, hPGK) situated immediately downstream of the translation
termination signal of the first gene. U3, R, U5 (LTRs) and HIV-1 cis-acting sequences are viral sequences necessary for viral genome packaging, reverse-
transcription and integration. Panel B. Experimental procedure of Retrovolution. White arrows indicate the initial steps of the procedure, lilac arrows
the steps involved in the generation of genetic diversity, and green arrows those involved in the selection steps. (a) HIV-based VSV-pseudotyped
defective vectors are generated by transfection of producer cells (HEK-293T cells) with two plasmids leading to the production of the viral proteins
(transcomplementation plasmids, pHCMV-G and pCMVDR8.91), and one or potentially more plasmids leading to the synthesis of the genomic RNA
(pSDY-dCK-Puro, outlined in panel A). The retroviral vectors generated (parental generation) are used to transduce (b) producer cells (HEK-293T) at a
high MOI. Expression of the puromycin-resistance gene from proviral DNA allows the selection of the efficiently transduced cell population (c). Upon
transfection of these cells with transcomplementation plasmids (d), new particles encapsidating the gRNA transcribed from the proviral DNA inserted
in the cell’s genome will be generated and used to transduce fresh producer cells (e). Steps (c), (d), and (e) are reiterated, producing subsequent viral
generations (each cycle requires a week in the case of puromycin selection, but this time varies with the selectable marker used). To screen the
library, some of the vectors are used to transduce the appropriate target cells at a low MOI (f). Transduced cells can then be directly screened on the
basis of the desired phenotype (g9) or they can first be selected for the expression of the selectable marker (with the possibility of isolating individual
clones or not) and subsequently selected based on the expression of the desired phenotype (g0).
doi:10.1371/journal.pgen.1002904.g001
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deoxycytidine analogue Gemcitabine, viral vectors from genera-
tion 16 were used to transduce HEK-293T cells at a low MOI
(MOI= 0.03) to ensure that each cell did not contain more than
one variant of the transgene, and single clones were isolated by
limiting dilution and puromycin selection. We then measured the
viability of 76 individual clones in the presence of increasing
concentrations of Gemcitabine (10, 35 and 70 nM) and calculated
the cell death rate as the number of alive cells at concentration X
of Gemcitabine divided by the number of cells at 0 Gemcitabine.
The experiment was repeated three times using, as controls, HEK-
293T cells either untransduced or transduced with a wt-dCK
containing vector. The two higher Gemcitabine concentrations
tested resulted to be too strong for an effective screening since all
samples, including controls, displayed more than 80% of cell death
(data not shown). At 10 nM Gemcitabine, instead, 6 of the 76
clones tested yielded, in at least one of the three independent
experiments, a cell death rate higher than both untransduced
HEK-293T cells and cells bearing the wt dCK transgene
(Figure 3A). These six clones were selected for further analysis.
The mutant G12 sensitizes different cancer cell lines to
Gemcitabine
The 6 clones isolated in the preliminary screening were further
characterized for the ability of their transgenes to induce
sensitization to Gemcitabine in the Messa10K cell line, uterine
sarcoma cells that express an inactive dCK and are, therefore,
highly resistant to this drug [13]. These cells provide an ideal
background for testing the ability of the library of dCK mutants to
increase sensitivity to Gemcitabine, since the phenotype generated
by the introduction of a single copy of a dCK variant will not be
masked by the activity of the wt dCK protein present in the cells.
For each HEK-293T clone selected, viral particles were rescued by
transfection with the plasmids encoding HIV-1 Gag-Pol and VSV
Env, and used to transduce Messa10K cells at a MOI,1. Since
the effect induced by a transgene on the cell phenotype can be
strongly influenced by the position of integration of the proviral
DNA within the target cell genome, transduction of the Messa10K
cells was performed following a procedure, outlined in Figure S1,
that generates, for each transgene, a population of cells containing
the same transgenic sequence inserted at different genomic
locations (‘‘polyclonal population’’). For each dCK variant
analysed we established 4 to 9 independent Messa 10K
populations with this procedure, that allows to average the
possible effects of the insertion site and to highlight the phenotype
induced by the transgenic sequence itself. From the analysis of cell
death ratios of Messa 10K populations in presence of increasing
concentrations of Gemcitabine appeared that one of the 6
transgenes identified on HEK-293T cells, G12 (E171K, E247K,
L249M), strongly sensitized cells to the drug. In the 9 G12-
Messa10K polyclonal populations tested, indeed, 50% of the cells
died at 75 nM Gemcitabine, while at the same concentration only
10% of Messa 10K containing a wt dCK were killed (Figure 3B).
The analysis of a broader range of Gemcitabine concentrations
revealed that in G12-Messa 10K cells the Gemcitabine IC50 was
reduced by 60-fold compared to cells transduced with wt-dCK,
and by 300-fold relative to untreated cells [13] (Figure 3C).
As shown by Western Blot (Figure 4A), sensitization of
Messa10K cells by G12 is not the consequence, as could result
from mutations in the EF1-alpha promoter (Figure 1A), of a higher
level of protein expression compared to wt-dCK. Nevertheless,
sequencing of the entire G12 gRNA revealed the presence of
mutations within as well as outside the dCK-cs and these
Figure 2. The system generates genetic diversity. Panel A. Expected relationship between the size of the target gene and the number of
Retrovolution cycles required to obtain a library containing one mutated position per virion in the gene sequence, based on the mutation rate of
3.461025 mutations per nt per cycle, described in the literature [3] (dashed line), and based on the rate observed experimentally in this work (solid
black line). Panel B. Distribution of the mutated positions within the dCK coding sequence (783 bp) found by sequencing 40 clones at generation 16.
Panel C. Position of the 12 mutations detected in the U3 region of the LTRs of all vectors sequenced starting from generation 8 (included).
doi:10.1371/journal.pgen.1002904.g002
Table 1. Mutation frequencies for the dCK gene at different steps of the Retrovolution procedure.
Generation
N6 of sequenced
clones
N6 mutated
positions
Relative mutation
rate
N6 of mutations
per clone
Average mut
positions/clone
F8 16 14 1.261024 0–5 0.88
F16 40 61 1.1461024 1–9 1.4
doi:10.1371/journal.pgen.1002904.t001
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mutations could influence the phenotype observed. To rule out
this possibility we inserted the G12 dCK-cs in a wild-type gRNA
backbone plasmid (generating ‘‘G12/wt-backbone’’ gRNA), and
tested the deriving viral vectors on Messa10K cells. Also in this
case a sensitization to the nucleoside analogue (Figure 4B) was
detected, indicating that the Gemcitabine sensitization phenotype
is rather due to properties of the dCK variant encoded by G12
than to mutations arisen in other portions of the genomic RNA.
Messa10K cells constitute a model of Gemcitabine-resistant
cells lacking an active endogenous dCK, as frequently emerge
during chemotherapy [15]. To investigate the effect of the
insertion of G12 in tumour cells that express an endogenous
functional dCK protein, we assessed the phenotype conferred by
the insertion of the mutated dCK to the colon carcinoma cell line
HT29, and to the pancreatic cancer cell line BxPC3. In HT29,
sensitivity to Gemcitabine is strictly linked to the levels of dCK
activity, whereas in BxPC3 the sensitivity to the prodrug depends
on a different mechanism, the expression levels of the cytidine
deaminase CDA [24,25], an enzyme that inactivates the fully
phosphorylated Gemcitabine by deamination. Therefore, while in
the former cells the insertion of an improved variant of dCK
should lead to a significant sensitization to the drug, in the latter
ones the effect should be reduced. We generated two independent
G12 polyclonal populations for each cell line and tested them.
Consistently with our hypothesis, we observed a considerably
stronger effect of G12 in HT29 than in BxPC3 (Figure 4C and 4D,
respectively), with a decrease in the Gemcitabine IC50 with
respect to cells containing a wt-dCK from 1.6 mM to 80 nM in
HT29 and only of less than two folds (from 40 to 22 nM) in
BxPC3. These results support the idea that the Gemcitabine
sensitization phenotype is due to an improved ability of the G12
mutated kinase to activate the prodrug in cell culture and
underscores that the insertion of a single copy of the transgene
can increase the sensitivity of cells to Gemcitabine even in the
presence of a wt dCK activity.
Change in substrate specificity of the G12 mutant
To further support the existence of a link between the effect of
the mutant in cell culture and its enzymatic activity, we expressed
in E. coli the G12 mutant and the wt type dCK proteins, purified
them and characterized their efficiency of phosphorylation of
Gemcitabine and of dC in vitro. While Gemcitabine was
phosphorylated with comparable efficiencies by the wt and G12
dCKs (left panel of Figure 5A), the natural substrate dC was
phosphorylated at almost undetectable levels by G12, with a
dramatic drop with respect to the efficiency of phosphorylation
observed with the wt dCK enzyme (right panel of Figure 5A). The
G12 dCK mutant therefore displays an altered substrate
specificity, constituting a kinase that specifically phosphorylates
Gemcitabine, even in the presence of the natural substrate of wt
dCK. These observations underscore that, in vivo, an increased
sensitivity to the prodrug can be efficiently achieved through a
decreased ability of the kinase to phosphorylate its natural
substrate, rather than through an improved efficiency of
Figure 3. Screening of the dCK library. Panel A. Viability of 76 isolated clones of HEK-293T transduced with the dCK-F16 viral library at a MOI,1
in the presence of 10 nM Gemcitabine. The different colors represent the percentage of dead cells on the total of seeded cells. Each line corresponds
to an independent experiment, and each column to one clone. The results obtained with untransduced cells and cells transduced with the wt-dCK
gene are given on the right (‘‘HEK-293T’’ and ‘‘wt-dCK’’, columns, respectively). Panel B. Viability of selected Messa10K ‘‘polyclonal populations’’ in the
presence of increasing concentrations of Gemcitabine. Thick pale blue line, untransduced Messa10K cells; thick red line, cells transduced with wt-dCK;
thin lines, cells transduced with the vectors derived from the clones identified in HEK-293T (Figure 1D): pink, B9; gray, B5; dark blue, F8; purple, G7;
orange, E8; green, G12. Values represent the ratio of the number of live cells over the total of cells seeded for each Gemcitabine concentration. For
each dCK variant, 4 to 9 populations of Messa10K cells were generated independently, as described in Figure S1, and for each population the
experiment was carried out in duplicate. For the sake of clarity, the error bars are shown only for samples G12 and wt-dCK. The values of G12 and wt-
dCK are significantly different for every Gemcitabine concentration tested (p,0.0001). Panel C. Cell death for Messa10K ‘‘polyclonal populations’’
either non-transduced (light blue) or transduced with the wt-dCK (red) or the G12 variant (green), with a larger range of Gemcitabine concentrations
than in panel B. The arrows indicate the IC50 values for Gemcitabine in the three different cell types.
doi:10.1371/journal.pgen.1002904.g003
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phosphorylation of the prodrug itself. So far, efforts at improving
the efficiency of phosphorylation of nucleoside analogues by dCK
have relied on the rational design of mutants either of the active
site region [19] or of Ser74, the phosphorylation of which has been
described to modulate the dCK enzymatic activity in vivo [20,26].
Although the resulting enzymes displayed an increased overall
catalytic activity in vitro, the relative efficiency of phosphorylation
(expressed as the ratio Kcat/KmGemcitabine/Kcat/KmdC) of the
drug with respect to the natural substrate was decreased compared
to the wt kinase, a trend opposed to that observed for the G12
mutant we describe (Figure 5B). Consistently with the view that
these mutants should not impact sensitivity of cells to Gemcitabine
treatment, when we constructed a vector carrying the sequence of
the triple mutant A100V/R104A/D133A [19] and used it to
transduce Messa10K cells, no altered sensitivity to Gemcitabine
was observed (Figure 5C).
Discussion
We describe here the development of a new system of
mutagenesis of cellular genes aimed at identifying genetic variants
of interest for applications in basic and applied research. A crucial
feature of the system is the possibility of performing, easily and in a
controlled manner, a straightforward screening of the library in
the human cell. This pragmatic approach allows to overcome the
generation of false positives variants, a frequent problem
encountered upon in vitro screening of libraries. The application
of the Retrovolution system led to the identification of a dCK
mutant that fulfils the long-sought feature of increasing sensitivity
of tumour cells to Gemcitabine treatment, based on the presence
of mutations unpredictable on a rational basis. The screening step
was performed following a protocol that ensures that the isolated
mutant sensitizes the cells independently from the integration site
Figure 4. The sensitization phenotype is due to a modified dCK activity. Panel A. Western Blot analysis of dCK expression levels in different
‘‘polyclonal populations’’. M: untransduced Messa10K cells; M-dCK: 4 Messa10K populations transduced with wt-dCK gene; M-G12: 4 Messa10K
populations transduced with the G12 variant. For each population 6,12 and 24 mg of total protein were loaded on the gel. Panel B. Gemcitabine
sensitivity of Messa10K cells transduced with vectors bearing the G12 mutant sequence inserted in a wild-type backbone. Triangles: untransduced
cells. Squares: cells transduced with wt-dCK. Empty circles: cells transduced with G12. Full circles: cells transduced with G12/wt-backbone. Results are
the average of 6 independent experiments. Panels C and D. Sensitivity to Gemcitabine of HT29 cells (panel C) and of BxPC3 cells (panel D) transduced
with one copy of G12 variant per cell. Triangles: untransduced cells. Squares: cells transduced with a wt-dCK vector. Circles: cells transduced with a
G12 vector. Results are the average of 2 independent experiments.
doi:10.1371/journal.pgen.1002904.g004
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of the provirus, therefore constituting a good candidate as ‘‘suicide
gene’’ in gene therapy.
The mutagenic potential of Retrovolution relies on the error-
prone nature of the replication machinery of HIV-1, and on the
frequent occurrence of recombination, that reshuffles the pre-
existing mutations contributing to increase the diversity of the
library. We show here that these two sources of genetic
diversification prompt enough diversity as to lead to the
identification of mutants of interest. With a relatively reduced
number of cycles the system allowed the creation of a library in
which each variant of the target gene was characterized by 1.5
mutated positions on average. A higher proportion of mutations
would have increased the chances of producing a high percentage
of non-functional proteins. An alternative approach for generating
a library of mutants of cellular genes contained in lentiviral vectors
would have been constituted first by a mutagenesis step of the
cellular gene through conventional methods as error-prone PCR,
followed by the insertion of the library in the lentiviral gRNA
plasmid. With respect to this approach, the method we describe,
while slower in the generation of a complex library, provides the
advantage of circumventing the unavoidable loss of complexity
inherent to the step of cloning the library in the lentiviral gRNA
plasmid. Another way to accelerate the acquisition of mutations
would have been the use of error-prone reverse transcriptases or
mild mutagens. These procedures were not privileged, though, due
to the inherent drawback of reduced yield of vector production
[27,28].
Depending on the nature of the target gene, the experimental
settings of Retrovolution can be adapted to introduce selection
ongoing during the mutagenesis steps. In the present work this was
not possible since we targeted a gene for which a negative
selection, as the induction of cell death, needed to be applied. The
targeting of the dCK gene was aimed, despite the intrinsic
difficulty of the screening procedure, at the isolation of variants of
a gene with a relevant biological interest for biomedical
applications. The properties of the mutant identified, indeed,
constitute the second major point emerging from this work.
Improving the efficiency of the currently clinically employed
anticancer drugs and overcoming resistances arising during
treatments is a major goal of cancer research. To improve the
efficiency of the treatments with nucleoside analogues like
Gemcitabine, gene therapy approaches aimed at sensitizing cancer
cells through the introduction of a transgene that improves the
efficacy of drug activation have been proposed. The hdCK is the
Figure 5. Biochemical characterization of G12. Panel A. Phosphorylation kinetics of wt-dCK and G12 mutant overexpressed in E.coli. Steady
state kinetic data of wt and G12 dCK fitted according to the Michaelis-Menten equation. Panel B. Ratio of the values of Kcat/Km for gemcitabine (Gem)
with respect to the values of Kcat/Km for the natural substrate dC for the triple mutant A100V/R104M/D133A, described in reference [19], for the S74E
mutant, described in reference [20], and for the G12 mutant, described here. The value found in each of the three studies for the wt dCK is given in
white, while that of the respective mutant is given in grey. Panel C. Viability of selected Messa10K ‘‘polyclonal populations’’ transduced with vectors
containing the wt dCK (squares), mutant G12 (circles), or the triple mutant A100V/R104M/D133A [19] (diamonds), and of untransduced Messa 10K
cells (triangles), in the presence of increasing concentrations of Gemcitabine.
doi:10.1371/journal.pgen.1002904.g005
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best candidate transgene for this purpose as the kinase is
responsible for the limiting step in intracellular activation of
deoxycytidine analogues currently used in clinical treatments. The
competition between the natural substrate of dCK and the prodrug
inside the cell constitutes an obstacle to the efficient activation of the
prodrug itself. The rational design of mutants in the catalytic site of
the kinase attained the goal of improving phosphorylation of the
prodrug in the past, but the mutants isolated displayed a
concomitant, and stronger, increase in the efficiency of phosphor-
ylation of the natural substrate [19,20]. As a result, phosphorylation
of the prodrug is expected to remain disfavoured with respect to the
natural substrate and these mutants fail, as we confirmed
(Figure 5C), to confer a drug sensitization phenotype to the cell.
The G12 mutant, on the contrary, has an increased specificity for
the phosphorylation of Gemcitabine due to the fact that it
completely lost the ability to phosphorylate its natural substrate.
This results in a reduction of the competition between the two
substrates in vivo and in a sensitization of the cells to the prodrug.
The biochemical mechanism through which an increased sensiti-
zation to the drug is obtained is therefore opposed to what generally
tried to obtain by engineering the dCK on a rational basis.
The screening for the isolation of the G12 mutant was
performed on Messa 10K cells, where the most striking
sensitization was observed. These cells constitute a model of
tumoral cells acquiring resistance to deoxycytidine analogues due
to a loss of dCK activity, a fundamental problem that has to be
bypassed for an improvement of cancer treatment. Nevertheless,
the G12 mutant has an effect also on tumour cells presenting an
endogenous dCK activity, like HT29 and HEK-293T. Therefore,
besides a potential application in cancer treatment, G12 also
constitutes a promising suicide gene to use as negative selection
marker in cells used in transplantation medicine. Suicide genes are
inserted in cells transplanted for therapeutical purposes to
specifically ablate them in the event they would undergo
uncontrolled proliferation in vivo. To this end exogenous genes
are generally used, the most frequently employed being the Herpes
Simplex Virus thymidine kinase gene in association with
gancyclovir treatment. A problem of increasing relevance in
clinical gene therapy, though, is constituted by the immune
response raised by the patient against the protein encoded by the
suicide gene [29,30]. A suicide gene of human origin, as the
mutant described here, is expected to have a faint possibility of
being highly immunogenic and therefore represents an ideal
candidate for this application.
Besides conferring an increased sensitivity to Gemcitabine
through an unexpected mechanism, the G12 mutant is charac-
terized by mutations localized in regions unpredictable on a
rational basis. The human dCK is a globular, dimeric protein in
which each monomer is formed by a core of 5 beta-sheets
surrounded by 10 alpha-helices [19] (Figure 6A). G12 dCK carries
the mutations E171K, E247K, and L249M, the first two of which
induce a charge change in conserved residues (Figure 6B). Amino
acids 247 and 249 are located in the ‘‘base-sensing loop’’ (alpha-
helix 10), which influences the folding of the protein upon binding
of ATP or UTP as phosphate donor [26,31] and, consequently,
also affects substrate binding. Indeed, a variant containing only
these mutations, which was identified during the screening of the
library (mutant E8, Figure 3B), slightly increased Messa10K cells
sensitivity to Gemcitabine treatment, although with a cell death
ratio that did not significantly differ from that of the wt-dCK
(p.0.05). The marked sensitization observed with G12 thus
requires the presence of the additional mutation, E171K. Residue
171 is located at the base of alpha-helix 7 that, with alpha-helix 4,
is involved in the generation of the interface of the dCK dimer
[19], and its mutation in a residue of opposite charge could
potentially influence the efficiency of formation of the active dimer
itself. Gel filtration analyses, though, revealed that the extent of
dimerization of G12 does not differ from that of the wt-dCK
(Figure S2). It is therefore likely that, as observed for other proteins
[32,33], the mutation rather triggers long-distance changes in the
quaternary arrangement of the protein, possibly involving the
region of the active site.
In conclusion, Retrovolution allowed the identification of a
promising suicide gene to use in cancer treatment but also as
negative selection marker in transplantation medicine by allowing
isolating a variant of the dCK that would not have been
predictable on a rational basis. The property of producing the
library and allowing its screening directly in human cells, ensuring
that each mutant emerging from the procedure will be relevant for
modifying the phenotype of the cells, is central to these findings.
Retrovolution thus opens new avenues for the modification of
genes conferring complex phenotypes of interest for a broad field
of applications in basic and applied research. With the exploitation
of its combination of genetic flexibility and ability to deliver
transgenes to human cells, the lifestyle of one of the most
important pathogens of our recent history appears far from being
fully exploited.
Materials and Methods
Cell lines
HEK-293T cells were obtained from the American Type
Culture Collection (ATCC) and grown in Dulbecco’s Modified
Eagle’s Medium (Gibco) supplemented with 10% FBS and 100 U/
ml pennicillin-100 mg/ml streptomycin. Messa10K cells were
kindly provided by LP. Jordheim and grown in RPMI medium
supplemented with 10% FBS and penicillin-streptomycin. HT29
cells were kindly given by JN. Freund and grown in DMEM+ 10%
FBS. BxPC3 cells were kindly provided by M. Dufresne and grown
in RPMI+ 10% FBS. All cells were incubated at 37uC+5% CO2.
Viral vectors production and transduction
For the creation of the first generation of viral vectors, 8 plates
containing 56106 HEK-293T cells were transfected using the
calcium phosphate protocol with 10 mg of pCMVDR8.91 plasmid
[34], 5 mg of pHCMV-G plasmid [34–36] and 10 mg of genomic
plasmid sdy-dCK (encoding the RNA outlined in Figure 1A). 48 h
after transfection, the virus-containing supernatant was collected,
filtered through a 0.45 mm filter and concentrated 40-fold in
Vivaspin 20 columns (MWCO 50 KDa, Sartorius Stedim
Biotech). Transfections for the creation of subsequent generations
were performed with 10 mg of pCMVDR8.91 and 5 mg of
pHCMV-G plasmid. Transductions during the evolution proce-
dure were performed on 5 million HEK-293T cells with 1 ml of
406 viral vectors (MOI.100). Transductions for the isolation of
single clones were performed with 1 ml of 1:500 dilution of viral
vectors (MOI,1) on 3.56106 HEK-293T cells; after transduction,
cells were seeded at 100 cells/well in 96-well plates in DMEM+
puromycin. For the generation of polyclonal populations of target
cells, transduction was performed on 16106 cells with 1 ml of 1:5
diluted viral vectors rescued from the isolated clones. Transduced
cells were selected by adding puromycin 24 h after transduction
using 0.6 mg/ml to HEK-293T cells, 0.5 mg/ml to Messa10K
cells, 0.8 mg/ml to HT29 cells and 0.4 mg/ml to BxPC3.
Amplification and sequencing of the dCK transgene
Clones of the F8 and F16 generation of the dCK library that
had been isolated by limiting dilution were expanded in 10 cm
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plates and pelleted. Cells were lysed with 250 ml of Cell Direct
PCR (VIAGEN). The dCK transgene was amplified from 1 ml of
the lysate with oligonucleotides on the vector, EF1 (59-gatgtcgtg-
tactggctccg-39) and PGK (5-gatgtggaatgtgtgcgagg-39), flanking the
transgene. Sequencing of the PCR fragment was performed by the
GATC sequencing service.
Library complexity calculations
The curves for the calculation of the number of Retrovolution
cycles needed to have one mutation per target gene (Figure 2A)
were drawn based on the formula p/m6n where p=nuof mutations
wanted per target gene, m=mutation rate/nt, n= size of the target
gene in nt.
Gemcitabine sensitivity test
Cells were seeded at 5000 cells per well in a 96-well plate and
grown overnight at 37uC. Two rows were used for each
population. 12 h after seeding, increasing concentrations of
Gemcitabine (0–400 nM or 0–100 mM) were added to each well
and incubation was continued for an additional 72 h. Cell viability
was measured by MTT test (CellTiter 96 Non-Radioactive Cell
Proliferation Assay, Promega) and the number of living cells in
each well was evaluated by measuring the OD at 570 nm. For
each population, the fraction of living cells was calculated as
OD570 concentration X Gem/OD570 concentration 0 Gem, to
estimate the sensitivity of the population to the prodrug.
Western blot analysis of dCK production in different
populations
Messa10K cells transduced with the different dCK variants
were lysed in 1X RIPA buffer, and 6, 12, 24 mg of total protein
(evaluated by Bradford) for each cell type were loaded on a 12%
bis-tricine gel (Invitrogen). After transfer on a PVDF membrane,
the dCK proteins were analysed by western Blot with 1:4000
dilution of a polyclonal anti-dCK antibody (rabbit, Sigma-Aldrich)
and 1:3000 anti-rabbit HRP (BioRad) conjugated secondary
antibody and detected by autoradiography.
Statistical analysis
To evaluate whether the average amounts of cell death
occurring in the Messa10K populations containing different
dCK variants were significantly different from the value shown
by Messa10K wt-dCK, a two sample t-test was applied for the
different concentrations of Gemcitabine.
Protein overexpression and purification
The wt-dCK and G12 sequences were cloned in the pET14b
plasmid and expressed in E. coli cells BL21 DE3 pLysE. Protein
expression was induced by adding 0.1 mM IPTG, and cells were
collected after 4 h of growth at 37uC. His-tagged proteins were
eluted with 250 mM Imidazole from His-Trap TM FF Columns
(GE HealthCare), the Histidine tag was removed using the S-Tag
Figure 6. G12 aminoacidic substitutions. Panel A. Diagram of a dCK monomer [38] designed with PyMol on 2N01 file of PDB. alpha-helices are in
blue, beta-sheets in green, phosphate donor and substrate in yellow. G12 mutations are highlighted in red and indicated by red arrows. Panel B.
ClustalW sequence alignment of human dCK, dGK, TK2 and of Drosophila melanogaster dNK. Yellow boxes highlight well-known structural elements
of the protein.
doi:10.1371/journal.pgen.1002904.g006
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Thrombin Purification Kit (Novagen), and dCK and G12 were
further purified by gel filtration on S-200 Sephacryl columns (GE
Healthcare). Purified proteins were used for the dCK activity assay
or stored at 280uC in 30% glycerol.
dCK phosphorylation activity
The efficiency of phosphorylation of the natural substrate
deoxycytidine and of the prodrug Gemcitabine were measured for
purified wt-dCK and G12 in a NADH-based assay as previously
described [37]. All reagents were purchased from Sigma (France)
except Gemcitabine (Lilly France SAS). Enzymes were assayed at
RT at a concentration of 0.3 mM with Gemcitabine or 0.9 mM
with dC. Gemcitabine was used at concentrations between 10 mM
and 1 mM and dC at concentrations between 5 and 50 mM. ATP
was 4 mM. All experiments were performed in triplicate.
Supporting Information
Figure S1 Screening procedure used for limiting the influence of
the retroviral insertion site and of insertional mutagenesis on the
expression of the cell phenotype. The first characterization of the
individual clones of HEK-293T cells, reported in Figure 3A, was
carried out on isolated clones whose cells contained a single
transgene inserted in the same genomic location. Each clone was
transfected with the plasmids encoding the viral proteins, to
generate a population of vectors that carried the same dCK
variant. These vectors were used to transduce cells (Messa10K
cells) at an MOI%1, giving rise to 20–100 clones for each
transgene, which were mixed and expanded, resulting in a
population of cells bearing the same dCK variant inserted in
different genomic sites (‘‘polyclonal population’’). For each HEK-
293T clone selected, 4 to 9 independent ‘‘polyclonal populations’’
of Messa10K cells were created and analyzed.
(PDF)
Figure S2 Gel filtration elution profile of wt and G12 dCK
proteins.
(PDF)
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